Endometriosis Drug Analysis and Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Endometriosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometriosis and special features on late-stage and discontinued projects.

Complete report on H1, 2015 Pipeline Review of “Endometriosis” addiction with 45 market data tables and 16 figures, spread across 127 pages is http://www.rnrmarketresearch.com/contacts/discount?rname=269524 . (This is a premium report price at US$2000 for a single user PDF license)

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Scope

·         The report provides a snapshot of the global therapeutic landscape of Endometriosis

·         The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

·         The report reviews key players involved in the therapeutics development for Endometriosis and enlists all their major and minor projects

·         The report summarizes all the dormant and discontinued pipeline projects

·         A review of the Endometriosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

·         Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

·         A detailed assessment of monotherapy and combination therapy pipeline projects

·         Coverage of the Endometriosis pipeline on the basis of target, MoA, route of administration and molecule type

Inquire for discount on this report at http://www.rnrmarketresearch.com/contacts/discount?rname=308857 .

Reasons to Buy:

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Endometriosis
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics

More reports on Women’s Health therapeutics :

2015 Market Research Report on Global Progesterone Industry

For international and China market analysis, the report analyzes Progesterone markets in China and other countries or regions (such as US, Europe, Japan, etc) by presenting research on global products of different types and applications, developments and trends of market, technology, competitive landscape, and leading suppliers’ and countries’ 2009-2014 capacity, production, cost, price, profit, production value, and gross margin. For leading suppliers, related information is listed as products, customers, application, capacity, market position, and company Contact information, etc. 2015-2020 forecast on capacity, production, cost, price, profit, production value, and gross margin for these markets are also included.

Complete report is available at http://www.rnrmarketresearch.com/2015-market-research-report-on-global-progesterone-industry-market-report.html .

CountryFocus: China Healthcare, Regulatory and Reimbursement Landscape Market

RnRMarketResearch.com add a new report “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – China”. The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in China. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets.

Considerable investment in China’s pharmaceutical Research & Development (R&D) sector, along with numerous government-initiated reforms, will spark soaring growth in the country’s pharmaceutical market in the near future. China is the most populated country in the world. In 2012, its population was approximately 1.3 billion, approximately one fifth of the global population. Growth has however been effectively controlled and has slowed down due to the strict enforcement of family-planning and one-child policies. The decline in the size of the young working-age group and the growing elderly population are however matters of concern for policy planners.

Complete report available @ http://www.rnrmarketresearch.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-china-market-report.html.

According to the company’s latest report on China’s healthcare industry CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – China, the country’s pharmaceutical market value will climb from an estimated $48 billion in 2012 to a massive $315 billion in 2020, at a Compound Annual Growth Rate (CAGR) of 26.5%. This increase will see China’s pharmaceutical market become the second largest in the world, with surging revenue propelling industry value significantly closer to that of the US, which GlobalData forecasts to reach $475 billion in 2020.

An expanding and aging population will also play a key role in boosting China’s pharmaceutical market revenue. With the country’s elderly population expected to account for 19% of its total population of 1.41 billion in 2020, GlobalData expects to see a rising prevalence of chronic diseases, which will in turn spark an increasing demand for treatment. This factor will also be a primary driver behind the rising value of China’s medical device market – the second largest in Asia, behind Japan – which forecasts will climb from $20 billion in 2012 to $54 billion in 2020.

This report identifies the key trends in China’s healthcare market, providing insights into the demographic, regulatory and reimbursement landscape and the country’s healthcare infrastructure, as well as the trends and segmentation of the Chinese pharmaceutical and medical device markets.

The report provides information on the healthcare, regulatory and reimbursement landscape in China, and includes –
- Overview of the pharmaceutical and medical devices markets, comprising market size, segmentation, and key drivers and barriers
- Profiles and SWOT analysis of the major players in the pharmaceutical market, of which the major Multinational Companies (MNCs) were GlaxoSmithKline (GSK), Pfizer, and AstraZeneca; and the major domestic players were Harbin Pharmaceutical Group and Tasly Pharmaceutical Group; and the medical device market, of which the major players were Siemens Healthcare, GE Healthcare, Fresenius Medical Care, GlaxoSmithKline, and Philips Healthcare
- Insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, regulatory agencies, and market authorization processes for new drugs and medical devices
- Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure, and healthcare expenditure
- An overview of the opportunities for and challenges to growth in the Chinese healthcare market

This report will enhance your decision-making capability by allowing you to –
- Develop business strategies by understanding the trends shaping and driving China’s healthcare market
- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical and medical devices market segments, and companies likely to impact the healthcare market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
- Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investments, and strategic partnerships
- Identify, understand and capitalize on the opportunities and challenges in China’s healthcare market

Purchase a report copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=111444.

Explore More Reports of Healthcare Market @ http://www.rnrmarketresearch.com/reports/life-sciences/healthcare